Literature DB >> 1585630

Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge.

H Ghiasi1, R Kaiwar, A B Nesburn, S Slanina, S L Wechsler.   

Abstract

We have constructed a recombinant baculovirus expressing high levels of the herpes simplex virus type 1 (HSV-1) glycoprotein E (gE) in Sf9 cells. The expressed gE migrated on gels as a double band with apparent molecular weights of 68 and 70 kDa. The recombinant gE was glycosylated based on its susceptibility to tunicamycin treatment and was transported to the membrane of Sf9 cells based on indirect immunofluorescence. Mice vaccinated with gE developed high serum titers of HSV-1-neutralizing antibodies based on plaque reduction assays. gE vaccination also induced a strong delayed type hypersensitivity (DTH) response to HSV-1. In addition, mice vaccinated with the recombinant gE were protected from both intraperitoneal and ocular lethal HSV-1 challenge. To our knowledge, this is the first report in which vaccination with gE was shown to induce high neutralizing antibody titers, a DTH response, or protection against lethal HSV-1 challenge.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585630     DOI: 10.1016/0042-6822(92)90500-o

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

Review 1.  Glycoprotein E of pseudorabies virus and homologous proteins in other alphaherpesvirinae.

Authors:  L Jacobs
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.

Authors:  A B Nesburn; S Slanina; R L Burke; H Ghiasi; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms.

Authors:  J K Olson; G A Bishop; C Grose
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.

Authors:  D M Koelle; M Schomogyi; C McClurkan; S N Reymond; H B Chen
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.

Authors:  A B Nesburn; R L Burke; H Ghiasi; S Slanina; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.

Authors:  M Fleck; J Podlech; K Weise; D Falke
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

7.  Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus.

Authors:  D N Love; C W Bell; D Pye; S Edwards; M Hayden; G L Lawrence; D Boyle; T Pye; J M Whalley
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1.

Authors:  M A Brehm; R H Bonneau; D M Knipe; S S Tevethia
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1.

Authors:  H Ghiasi; S L Wechsler; R Kaiwar; A B Nesburn; F M Hofman
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.

Authors:  J E Blaney; E Nobusawa; M A Brehm; R H Bonneau; L M Mylin; T M Fu; Y Kawaoka; S S Tevethia
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.